Purpose: To determine if the treatment planning computed tomography scan (CT) from an initial intracranial stereotactic radiosurgery (SRS) treatment can be used for repeat courses of SRS.
| INTRODUCTION
Up to 40% of cancer patients will develop brain metastases over the course of their illness. 1 Brain metastases are generally managed with some combination of surgery, whole brain radiotherapy (WBRT), stereotactic radiosurgery, and steroids. 2 In a radiotherapy setting, SRS offers durable local control with the possibility of reduced neurocognitive impairment compared to WBRT or a combination of WBRT and SRS. 3 However, the use of SRS alone carries an increased risk of distant brain recurrence versus WBRT, which necessitates active monitoring and follow-up for patients that have been treated with SRS alone (see [2] and Refs. within).
The risk for subsequent metastasis following initial SRS may approach 50%-60%, and these recurrences may be amenable to SRS for salvage.
A typical course of care for a patient treated with linear accelerator based SRS is to undergo magnetic resonance (MR) and a computed tomography (CT) scans prior to an initial treatment with SRS, then to be followed with interval MR imaging. If new metastases are found on review of the interval MR images, the patient returns for a radiotherapy planning CT. After a short period for treatment planning, the patient will undergo salvage SRS treatment.
The primary purposes of radiotherapy planning CTs are to provide information on electron transport for dose calculations and to aid in patient localization during treatment through registration to a cone beam CT (CBCT) or the creation of digitally reconstructed radiographs (DRRs). If these tasks could be fulfilled without the need for a CT, the patient might save the financial cost of the imaging, the radiation dose, and trips to the radiation oncology department associated with a planning CT.
A number of different methods have been used to calculate dose without a CT scan. Treatment planning systems such as GammaPlan for the Gamma Knife (Elekta AB, Stockholm, Sweden) have employed dose calculation models that treated the patient as homogenous media. This system modeled dose to better than 5% accuracy in the absence of air cavities and high density heterogeneities as shown by Monte Carlo simulations. [4] [5] [6] In this case, localization was typically provided by stereotactic head frame. Efforts have been made to create "synthetic" or "pseudo" CTs from MR images that can be used for dose calculation and localization. [7] [8] [9] [10] [11] [12] [13] [14] These methods show promise in terms of geometric and dosimetric accuracy, but are not in widespread clinical use at this time.
Brain metastases are difficult to visualize on CBCT or planar xray images used for patient localization in linear accelerator-based SRS. Because of this, the skull is typically used to align images in the registration process for SRS set-up. The CT simulation impacts the patient and the radiation oncology department on financial and social levels. In terms of the patient, a treatment planning CT may duplicate information in existing diagnostic studies or previous radiation planning CT scans. If prior information could be used, the patient in theory, could be treated on the same day as a follow-up visit with the radiation oncologist. This would save the patient 1-2 trips (separate treatment planning and treatment delivery visits could be avoided) and multiple hours in the department. Removal of the CT simulation process would also result in a financial savings for the patient. The radiation oncology department would benefit from increased patient throughput and the freedom to plan the treatment without the time pressure associated with a fixed date range between a CT simulation appointment and a treatment delivery appointment. This change in practice may also offer financial benefit to the clinic as we move toward value-based reimbursement models.
In this work, we evaluate the impact on dosimetry and localization of using an initial CT for repeat SRS planning and delivery.
| METHODS AND MATERIALS
A total of 25 patients that received repeat courses of SRS were retrospectively reviewed. The accuracy of using repeat MR scans (rMR) and initial SRS CT scans (iCT) for target definition and treatment localization at repeat treatments were evaluated. The dosimetric accuracy of using iCTs for dose calculation versus repeat SRS CT scans (rCT) was evaluated. 
2.A | Targeting accuracy
Linear accelerator SRS patients are localized using a skull-based setup with a CBCT or DRRs. For set-up with an iCT at repeat SRS, the skull must be nearly identical in the iCT and rCT to allow for accurate registration of volumetric images or creation of DRRs. We evaluated the similarity of the skull shape, orientation, and the ability to align the skull between the iCT and the rCT using ray traces from For SRS target definition using an iCT, the intracranial soft tissue targets defined on the rMR must be accurately positioned on the iCT scan relative to the skull, which is based on an iCT to rMR registration. The ability to register the rMR to the iCT was evaluated in a multistep process: (a) the rMR was registered to the rCT using all anatomy, (b) the rMR was registered to the iCT primarily using bony anatomy, (c) the iCT was registered to the rCT, (d) the residual shifts to align the rMR image set from the registrations in steps 1 and 2
were found. Here, we assume that the iCT to rCT registration is perfect, so that the residual shifts to align the rMR image sets represent the uncertainty in the rMR to iCT registration process. All registrations were performed manually by a board certified medical physicist. The registration process, with examples of typical registrations, is outlined in Fig. 1 .
2.B | Dosimetric accuracy
The dosimetric accuracy using a rCT scan depends on the similarity of the information in the rCT as compared to the iCT. The similarity of the iCT and rCT image sets were compared using the mutual information (MI) and Pearson's correlation (PC) coefficients generated by MIM Maestro in the registration process. 15 The iCT to rCT metrics were compared against groups of SRS patients that All other patients had CT scans on the Philips system as described above.
The relationships between MI and PC to time between CT scans were evaluated using Pearson's r value. Correlation values of |r| < 0.4 were considered weak, 0.4 < = |r| < = 0.7 intermediate, and
|r| > 0.7 strong. Statistical significance was defined as P < 0.05. The two dose distributions were compared through 3D gamma analysis. 16 The gamma analysis was carried out in custom software written in Matlab. To perform the gamma analysis, the doses from the iCT and rCT calculations were exported in DICOM format to an offline computer. Gamma analysis was performed with a 1 mm distance to agreement (DTA) and a 1% dose agreement percentage.
The dose evaluations were based on the global maximum dose. The 1 mm 3 dose grid was resampled to 0.2 mm 3 for the gamma evaluation. All dose points greater than 10% of the maximum dose were considered.
The relationships between gamma passing rates and time between scans, as well as the relationships between gamma passing rates and target volume were evaluated using Pearson's r value. Correlation strengths are defined as above.
This work was carried out with the approval of the Cone Health institutional review board under protocol number 1741.
| RESULTS
A total of 30 different CT scans were compared from the 25 SRS patients (some patients had rCTs at multiple time points). The mean time between iCT and rCT was 220 AE 189 days (1 STD) (range 65-979 days). Contrast was administered on all MR scans. Contrast was used on both the iCT and rCT in 22 cases, on either the iCT or rCT in six cases, and on neither CT in two cases.
3.A | Targeting accuracy
The directions of the ray traces used to evaluate the distance from each target to the proximal skull surface are shown in Fig. 2 . The mean absolute difference in distance from target to skull between the iCT and rCT scans over the 640 samples from all patients and all rays was 0.3 AE 0.6 mm (range 0-3.2 mm). The mean absolute difference in distance over all rays for each patient, averaged over all patients, was 0.3 AE 0.2 mm (range 0-0.9 mm).
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The magnitude of the residual linear translations over the 30 rMR registrations was 0.6 AE 0.3 mm. Only, six of the cases had displacements >1 mm in magnitude. The full set of mean linear translations and rotations for the rMR image sets are shown in Table 1 .
3.B | Dosimetric accuracy
The 
| DISCUSSION
For the iCT to be used for localization at repeat treatments, the skull shape and orientation must be stable and reproducible between the iCT and rCT, so that registrations between CBCT and iCT (or between planar x-rays and DRRs generated from the iCT) are accu- | 255 when no appreciable anatomic differences exist between the scans.
For example, multiple scans acquired within minutes of each other will not be identical due to changes in the image acquisition.
Because of these issues MI and PC, admittedly, are not ideal metrics to evaluate anatomic similarity between two specific image sets.
However, when considering multiple registrations the increased number of samples helps to reduce the impact of the variable interscan parameters described above and allows MI and PC to give useful information about processes or trends. The CT number differences between the iCT and rCT are typically local to the target and likely produce dose changes <1%.
The gamma values did show a moderate correlation with time.
However, all of the gamma values were high, indicating good agreement between iCT and rCT doses at all times. Also, the lowest gamma score (96.5%) occurred at the greatest time point (979 days).
If this point is dropped from the analysis, there is no significant correlation. As described above, there appears to be no correlation with time for up to 400 days, and likely minimal effect beyond 400 days.
We are not aware of other work investigating the use of prior CT images for radiotherapy dose calculations. These studies used 2D gamma analyses to evaluate relatively large and homogeneous (relative to the lower volume, high gradient cases in this work) dose distributions. The 2D gamma analyses should lead to lower passing rates than the 3D method used in this work, while the more homogeneous dose distributions for primary brain tumors should give higher gamma passing rates.
Due to these differences, it is not easy to directly compare dose calculations on iCT to these dose calculations on synthetic CTs.
However, the comparatively high gamma rates observed in this work strongly suggest that iCT dose calculations are at least as accurate as dose calculations on synthetic CTs for intracranial treatments. With accurate localization, the level of dose agreement found between iCTs and rCTs is certainly adequate for SRS.
The primary treatment concern at repeat treatment would be | 257
Use of the iCT for localization and dose calculation should be carefully evaluated in the presence of surgical intervention between initial and repeat treatments. Changes in intracranial soft tissue due to surgery are not likely to have a marked impact on the dose calculation, as changes in edema were not found to have a big impact on dosimetry. However, the introduction of clips, burr hole covers, or changes to the skull can impact image registrations for target definition and set-up, and should be carefully considered.
Similar ideas could be applied to other disease sites. For example, palliative bone metastases might be planned based on MR or diagnostic CT scans with acceptable dosimetric and localization accuracy.
Further study is planned in this area.
| CONCLUSIONS
The use of iCT and rMRs for repeat treatment planning is feasible and easy to implement. This process allows for target delineation, dose calculation, and set-up that is adequate for SRS. It may offer time and cost savings to both the patient and the clinic.
